Standout Papers
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial (2021)
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (2020)
Immediate Impact
3 by Nobel laureates 26 from Science/Nature 70 standout
Citing Papers
From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors
2024 StandoutScience
Works of Changgui Li being referenced
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
2020 Standout
Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Changgui Li | 1244 | 1683 | 517 | 517 | 99 | 2.9k | |
| Michal Mandelboim | 1220 | 2201 | 1137 | 391 | 155 | 4.8k | |
| Joanna Ellis | 3188 | 1668 | 395 | 470 | 111 | 4.7k | |
| Denise Naniche | 1788 | 1490 | 924 | 227 | 103 | 3.7k | |
| Wilbur H. Chen | 981 | 1276 | 816 | 195 | 86 | 2.8k | |
| Miao Xu | 376 | 2073 | 407 | 284 | 68 | 2.8k | |
| Fatima Amanat | 987 | 2727 | 624 | 251 | 55 | 3.7k | |
| Helen Y. Chu | 1481 | 3122 | 465 | 320 | 138 | 4.8k | |
| Ralf Clemens | 2296 | 1911 | 684 | 454 | 138 | 4.8k | |
| Chris Ka Pun Mok | 1096 | 2239 | 604 | 131 | 84 | 3.2k | |
| Emma C. Thomson | 799 | 2797 | 280 | 191 | 85 | 3.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...